What is the current Price Target for the Structure Therapeutics stock?

The average Structure Therapeutics target price is $78.04. This is 377.88% higher than the current stock price. The highest price target is 622.60%, the lowest is 160.26%. 13 Analysts have issued a price target Structure Therapeutics 2026 .

How high will the Structure Therapeutics stock rise?

No reliable answer can be given as to how high the Structure Therapeutics stock will rise. The performance of stocks, including the Structure Therapeutics stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Structure Therapeutics stock today?

The performance of Structure Therapeutics stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Structure Therapeutics stock fall?

The decline in Structure Therapeutics stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Structure Therapeutics Forecast, price target & analysts

$16.33

3.66% yesterday

Nasdaq, Apr 03, 10:00 pm CET

ISIN

US86366E1064

Symbol

GPCR

Reports

Quarter | Annual

Sector

Services

Industry

Various services

Overview Dividends Analysts Charts News Strategies

Structure Therapeutics Target price 2025 - Analyst rating & recommendation

Structure Therapeutics Classifications & Recommendation:

Buy

100%

Structure Therapeutics Price Target

Target Price	$78.04
Price	$16.33
Potential	377.88% register free of charge
Number of Estimates	13

	13 Analysts have issued a price target Structure Therapeutics 2026 . The average Structure Therapeutics target price is $78.04. This is 377.88% register free of charge higher than the current stock price. The highest price target is $118.00 622.60% register free of charge , the lowest is $42.50 160.26% register free of charge .
	A rating was issued by 13 analysts: 13 Analysts recommend Structure Therapeutics to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Structure Therapeutics stock has an average upside potential 2026 of 377.88% register free of charge . Most analysts recommend the Structure Therapeutics stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-2.33	-1.09
	4.51%	53.22%
P/E		negative
EV/Sales		1.23

4 Analysts have issued a Structure Therapeutics forecast for earnings per share. The average Structure Therapeutics EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-2.33	4.51%
2025	$-1.09 53.22% Unlock
2026	$-2.17 99.08% Unlock
2027	$-2.95 35.94% Unlock
2028	$-1.53 48.14% Unlock
2029	$1.03 167.32% Unlock

Current	-7.05	58.75%
2025	-15.05 113.48% Unlock
2026	-7.53 49.97% Unlock
2027	-5.54 26.43% Unlock
2028	-10.67 92.60% Unlock
2029	15.85 248.55% Unlock

Structure Therapeutics...

Current Structure Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Citizens Capital Markets	Locked ➜ Locked	Locked	Feb 28 2025
William Blair	Locked ➜ Locked	Locked	Feb 28 2025
Stifel	Locked ➜ Locked	Locked	Jan 08 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Dec 20 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Dec 19 2024
JMP Securities	Locked ➜ Locked	Locked	Dec 18 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Dec 04 2024

Analyst Rating	Date
Locked Citizens Capital Markets: Locked ➜ Locked	Feb 28 2025
Locked William Blair: Locked ➜ Locked	Feb 28 2025
Locked Stifel: Locked ➜ Locked	Jan 08 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Dec 20 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Dec 19 2024
Locked JMP Securities: Locked ➜ Locked	Dec 18 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Dec 04 2024

Discover more stocks with a high price target

Coinbase Global, Inc. 83.53%

BioNTech SE - ADR 50.09%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now